secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bicara Therapeutics Inc. (BCAX)
CIK:        0002023658
Form:       8-K
Filed at:   2026-05-11T23:59:59+00:00
Accession:  0001628280-26-033135
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicara Q1 net loss $56.2M; cash $539.8M; appoints new CMO and CCO; advances ficerafusp alfa
--------------------------------------------------------------------------------

- Net loss of $56.2M for Q1 2026 vs $36.8M YoY; R&D expenses $47.5M, G&A $12.7M.
- Cash and marketable securities $539.8M at March 31, 2026; raised ~$161.8M in public offering.
- Bill Schelman promoted to CMO; David Raben transitions to Senior Executive Advisor; Chris Sarchi appointed CCO.
- Plan to initiate randomized study of ficerafusp alfa + pembrolizumab with loading and Q3W maintenance in 1L R/M HPV-negative HNSCC in Q3 2026.
- FORTIFI-HN01 pivotal trial substantially enrolled by year-end; interim analysis mid-2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023658/000162828026033135/0001628280-26-033135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023658/000162828026033135/bcax-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-033135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer